Skip to main content
SpringerLink
Log in

Economic, Public Health, and Policy Implications of Hematopoietic Growth Factors, High-dose Chemotherapy, and Stem Cell Rescue

  • Chapter
Clinical Applications of Cytokines and Growth Factors

Part of the book series: Developments in Oncology ((DION,volume 80))

  • 111 Accesses

Abstract

The use of hematopoietic growth factors (HGF) and high dose therapy with stem cell transplant (SCT) are two relatively new weapons in the battle against cancer that have gained widespread acceptance among oncologists in the United States and abroad. HGFs, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), have been shown to reduce the time to hematopoietic recovery following myelosuppressive chemotherapy and SCT for both solid tumors and hematopoietic malignancies. These new technologies have improved patient outcomes, but are also relatively costly. Their development has resulted in a myriad of economic, public health, and policy concerns related to costs, regulation, legislation, and access to care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McVie JC. Counting costs of care. J Clin Oncol 6: 1529–1531, 1988.

    PubMed  CAS  Google Scholar 

  2. Eisenberg JA. Clinical economics. Ag guide to the economic analysis of clinical practice. JAMA 262:2879–2886, 1989.

    Article  PubMed  CAS  Google Scholar 

  3. Drummond M, Stoddart G, LaBelle R et al. Health economics: an introduction for clinicians. Ann Intern Med 107: 88–92, 1987.

    PubMed  CAS  Google Scholar 

  4. Smith TJ, Desch CE, Hillner BE. Analysis of economic issues. In High dose cancer therapy: Pharmacology, Hematopoietins, and stem cells. (Antman K, Armitage JO eds). Philadelphia: Williams and Wilkins, 1992.

    Google Scholar 

  5. Goddard M, Hutton J. Economic evaluation of trends in cancer therapy: Marginal or average costs. Int J of Tech Assessment in Health Care. 7: 594–603, 1991.

    Article  CAS  Google Scholar 

  6. Wodisnky HB. The costs of caring for cancer patients. J of Palliative Care 8: 24–27, 1992.

    Google Scholar 

  7. Robinson R. Economic evaluation and health care: Costs and cost-minimization analyses. BMJ 307: 726–728, 1993.

    Article  PubMed  CAS  Google Scholar 

  8. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q 60: 429–462, 1982.

    Article  CAS  Google Scholar 

  9. Weber RJ. Pharmacoeconomic issues in the use of GM-CSF for bone marrow transplantation or chemotherapy-induced neutropenia. Clin Ther 15:180–91, 1993.

    PubMed  CAS  Google Scholar 

  10. Bennett CL, Westerman IL. Economic Analysis During Phase III Clinical Trials: Who, What, When, Where and Why? Oncol 9(11):1–7, 1995.

    Google Scholar 

  11. Fayers PM, Hand DJ. Generalisation from Phase III Clinical Trials: Survival, Quality of Life, and Health Economics. Lancet 350:1025–27, 1997.

    Article  PubMed  Google Scholar 

  12. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488–93, 1993.

    Article  PubMed  CAS  Google Scholar 

  13. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence based, clinical practice guidelines. J Clin Oncol 12: 2471–2508, 1994.

    Google Scholar 

  14. Riikonen P, Rahiala J, Salonvaara M, et al. Prophylactic administration of granulocyte colony-stimulating factor after conventional chemotherapy in children with cancer. Stem Cells 13:289–94, 1995.

    Article  PubMed  CAS  Google Scholar 

  15. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781–87, 1997.

    Article  PubMed  CAS  Google Scholar 

  16. Pajeau TS, Lane D, Bennett CL, et al. Economic Analysis of G-CSF use with Intensive Treatment for Pediatric Lymphoma and T-Cell Leukemia. Blood 90(10) Suppl. 1:316–1.

    Google Scholar 

  17. Bennett CL, Golub RM, Waters TM, et al. Economic analyses of phase III cooperative cancer group clinical trials: Are they feasible? Cancer Invest 15:227–36, 1997.

    Article  PubMed  CAS  Google Scholar 

  18. Woronoff-Lemsi MC, Demoly P, Arveux P, Ifrah N, Tellier Z, Harousseau JL, Cahn JY, Witz F. Cost-effectiveness analysis of GOELEM SA3, a randomized placebo-controlled protocol of GM-CSF for elderly patients with acute myeloid leukemia. Blood 90(10) Supplement 1:72a, 1997.

    Google Scholar 

  19. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony stimulating factor administration in older patients with non-Hodgkin’s lymphoma treated with combination chemotherapy. Ann Oncol 5:127–132, 1994.

    Article  PubMed  Google Scholar 

  20. Uyl-de Groot CA, Vellenga E, de Vries EG, et al. Treatment costs and quality of life with granulocyte-macrophage colony stimulating factor in patients with antineoplastic therapy-related febrile neutropenia, Pharmacoecon 12:351–60, 1997.

    Article  Google Scholar 

  21. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87:803–08, 1995.

    Article  PubMed  CAS  Google Scholar 

  22. Mitchell PLR, Morland B, Stevens MCG, et al. Granuloycyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 15(3): 1163–70, 1997.

    PubMed  CAS  Google Scholar 

  23. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed Hodgkin’s disease. Ann Intern Med 116:177–82, 1992.

    PubMed  CAS  Google Scholar 

  24. Luce BR, Singer JW, Weschler JM, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. Pharmacoecon 6:42–48, 1994.

    Article  CAS  Google Scholar 

  25. Souetre E, Qing W, Penelaud PF. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur J Cancer 32A:1162–65, 1996.

    Article  PubMed  CAS  Google Scholar 

  26. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031, 1993.

    PubMed  CAS  Google Scholar 

  27. Faucher C, le Corroller AG, Blaise D, et al. Comparison of G-CSF primed peripheral blood progenitor cells and bone marrow autotransplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 14:895–901, 1994.

    PubMed  CAS  Google Scholar 

  28. Uyl-de Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilized by G-CSF: A less costly alternative to autologous bone marrow transplantation. Eur J Cancer 30A.1631–35, 1994.

    Article  Google Scholar 

  29. Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. J Clin Oncol 15:5–10, 1997.

    PubMed  CAS  Google Scholar 

  30. Rundle RL. Salick pioneers selling cancer care to HMOs. The Wall Street Journal, Monday August 12:B1–B2, 1996.

    Google Scholar 

  31. Mortenson LE. Health care policies affecting the treatment of patients with cancer and cancer research. Cancer 74:2204–07, 1994.

    Article  PubMed  CAS  Google Scholar 

  32. De Lima M, Strom SS, Keating M, et al. Implications of potential cure in AML: Development of subsequent cancer and return to work. Blood 90:4719–24, 1997.

    PubMed  Google Scholar 

Download references

Authors
  1. Charles L. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tammy J. Stinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Division of Hematology/Oncology, University of Florida College of Medicine, Shands Hospital, Gainesville, FL, 32610, USA

    John R. Wingard M.D. (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA

    George D. Demetri M.D. (Assistant Professor of Medicine) (Assistant Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bennett, C.L., Stinson, T.J. (1999). Economic, Public Health, and Policy Implications of Hematopoietic Growth Factors, High-dose Chemotherapy, and Stem Cell Rescue. In: Wingard, J.R., Demetri, G.D. (eds) Clinical Applications of Cytokines and Growth Factors. Developments in Oncology, vol 80. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5013-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5013-6_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7277-6

  • Online ISBN: 978-1-4615-5013-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation